|Day Low/High||22.74 / 23.09|
|52 Wk Low/High||17.69 / 24.43|
Here's a slideshow of 10 housing stocks as homebuilder sentiment rises to 70 in May, with single-family housing starts below its long-term potential.
Here are Wednesday's top research calls, including new coverage of Advanced Micro Devices and Transocean, upgrades for Clovis Oncology and ConocoPhillips, and a downgrade for Disney.
Pharma Mar S.A. Submitted the Marketing Authorisation Application in the European Union at the end of 2016
Planned Governance Succession Complete as Bryce Blair Becomes Non-Executive Chairman
Opening in February 2018, Del Webb Myrtle Beach at Grande Dunes is Located on the Oceanside of the Intercoastal Waterway
The White House's decision to put tariffs on Canadian softwood lumber imports could have stocks moving in the days and weeks to come.
Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.
Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.
A study of analyst recommendations at the major brokerages shows that PulteGroup Inc is the #73 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.
A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.
Some kind of spending deal will have to be in place by Saturday in order to avoid the mayhem.
Book profits on homebuilder stocks as builder sentiment falls 3 points in April, while single-family starts slip in March.
The large U.S. homebuilder quietly disclosed that its lead independent director was not renominated, a major victory for activist Elliott Management.
The stock has been on the rise, but there may not be enough upside.
The biopharmaceutical company has reported new data on the mechanism of action of plitidepsin and lurbinectedin